크레오에스지

040350KOSDAQ컴퓨터 프로그래밍, 시스템 통합 및 관리업

46.3 / 100

Reference Date: 2026-07-24

Financial Score6.0 / 40

News Sentiment21.3 / 25

Momentum7.0 / 20

Disclosure12.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 27.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Creo SG operates in three main business segments: financial IT solutions, biotech vaccine development, and real estate operations. The solution segment provides core banking systems to banks and non-banks, while the biotech segment focuses on developing vaccines for AIDS, COVID-19, and superbugs, though it currently generates no revenue. The real estate segment manages properties through a subsidiary.

Number of Employees

48people

Average Salary

57.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 12.944.0Point

PBR

3.15Industry Average 0.720.0Point

4.4x industry avg (risky)

ROE

-17.52Industry Average 6.290.0Point

Well below industry avg

Debt Ratio

69.35Industry Average 10.070.0Point

6.9x industry avg (risky)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼32.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -30.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
크레오에스지, 메르스 백신 캐나다 특허 취득
크레오스지의 메르스 백신 특허 취득으로 기술 경쟁력 강화 및 미래 백신 개발 가능성이 높아져 긍정적 영향 기대.

Detailed Momentum

52-week position6.0Point

52w upper range (60%)

Current 7,500Won52-week high 11,95052-week low 556

1-month return0.0Point

1m -27.11% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 1Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-15
Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-07-10
Neutral조회공시요구(현저한시황변동)에대한답변(미확정)2026-07-09
Neutral전환청구권행사 (제22회차)2026-07-06